Primex Pharmaceuticals AG Logo
2016-02-24 16:20
Primex Pharmaceuticals: New Acquisition Brings an Innovative Oral Solution for Pediatric Anesthesiology to the Market
ZUG, SWITZERLAND & NIMES, FRANCE--(Business Wire/Korea Newswire) February 24, 2016 -- Swiss pharmaceutical company Primex Pharmaceuticals AG and French pharmaceutical laboratory Advicenne SA announced today a deal where Primex will acquire global rights for an advanced oral pharmaceutical candidate for pediatric anesthesiology developed by Advicenne. The market potential is evaluated as hundreds of millions of euros.

This oral solution is dedicated to pediatric anesthesiology. Nearly 10,000 patients have already been successfully treated by the university hospital at Amiens, which collaborated with Advicenne.

With this acquisition, Primex Pharmaceuticals expands its anesthesiology portfolio with a unique product that will be distributed through Primex’s existing channels and new partners, which will be appointed in all other markets.

“This is a breakthrough in the area of pediatric anesthesia, and along with further applications, the annual market potential is between 100 M€ and 350 M€”, says Kari Sarvanto, President of Primex Pharmaceuticals. “We’re extremely enthusiastic about the cooperation with Advicenne and looking forward to bringing such a patient-friendly novel product to the market.”

“As one of the very first in-house developed products, this deal validates our strategy and capabilities in developing original pediatric-adapted drugs”, says Dr Luc-André Granier, CEO of Advicenne. “Primex Pharmaceuticals is probably the best partner for the commercial success of the product as its network is global and its commitment for anesthesiology is very strong.”

About Advicenne,

Advicenne, a fast-growing specialty pharma, focuses on innovative pediatric medications, targeting orphan or neglected diseases within the fields of neurology and nephrology and aims to become a world leader in those therapeutic areas.

The company has today a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and epilepsy, and has started its commercial activities late 2015 with its first product on the French market.

About Primex Pharmaceuticals

Primex Pharmaceuticals is a fast-growing company spearheading a new pharmaceutical business model. It supplies high-quality anesthetics and life-saving medicines to healthcare institutions and professionals around the world. Primex’s distribution reaches a population of nearly one billion people. The company is headquartered in Finland and Switzerland.

Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth (29 % CAGR in 2012-2015E) and high margins (adjusted EBITDA margin 12% on average 2012-2015E).

View source version on
Primex Pharmaceuticals AG 전체 보도자료 보기
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

Primex Pharmaceuticals
Mr Kari Sarvanto, President
Mobile: +41 796 162 694

For Advicenne
Ms Adélaïde Manester
Mobile: +33 1 58 18 32 44
+33 6 70 45 74 37

Ms Anne Hardy
Mobile: +33 1 58 18 32 51
+33 6 13 56 23 96

이 보도자료 관련 분야

건강  제약  인수/합병  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.